Research Interest: Pharmacology

PHD PROGRAM
Neuroscience, Pathobiology & Translational Science

RESEARCH INTEREST
Behavior, Neurobiology, Pharmacology, Physiology, Translational Medicine

Early life and adult pain can have drastic effects on neurodevelopment and overall quality of life. In the Williams’ Pain, Aging, and Interdisciplinary Neurobehavioral (P.A.I.N.) Lab, our research focuses on behavioral neuroscience and the mechanisms of neurobiology and neurophysiology of pain processing, with a special emphasis on the neonatal. The ultimate research goal is to better understand, recognize, and alleviate pain in the newborn to improve the quality of life in adulthood by uncovering new assessment tools and interventional strategies. Our research interests include the mechanisms of neurobiology and neurophysiology of pain processing, neonatal pain, chronic pain, neurobehavior, osteoarthritis, translational medicine, anesthesia/analgesics, and evoked and non-evoked pain assessment tools. The P.A.I.N. Lab has both pre-clinical and clinical studies to help close the gap in translation.

PHD PROGRAM
Bioinformatics & Computational Biology, Chemistry, Pharmacology

RESEARCH INTEREST
Biochemistry, Bioinformatics, Biophysics, Cancer Biology, Computational Biology, Genomics, Pharmacology, Structural Biology, Systems Biology, Translational Medicine

A growing body of work in the biomedical sciences generates and analyzes omics data; our lab’s work contributes to these efforts by focusing on the integration of different omics data types to bring mechanistic insights to the multi-scale nature of cellular processes. The focus of our research is on developing systems genomics approaches to study the impact of genomic variation on genome function. We have used this focus to study genetic and molecular variation in both natural and engineered cellular systems and approach these topics through the lens of computational biology, machine learning and advanced omics data integration. More specifically, we create methods to reveal functional relationships across genomics, transcriptomics, ribosome profiling, proteomics, structural genomics, metabolomics and phenotype variability data. Our integrative omics methods improve understanding of how cells achieve regulation at multiple scales of complexity and link to genetic and molecular variants that influence these processes. Ultimately, the goal of our research is advancing the analysis of high-throughput omics technologies to empower patient care and clinical trial selections. To this end, we are developing integrative methods to improve mutation panels by selecting more informative genetic and molecular biomarkers that match disease relevance.

PHD PROGRAM
Pathobiology & Translational Science

RESEARCH INTEREST
Bioinformatics, Cancer Biology, Genomics, Pharmacology, Translational Medicine

Our laboratory is focused on translating novel molecular biomarkers into clinical oncology practice, with the overarching goal of improving the care and survival of patients with cancer. Our group is highly collaborative and applies genomic, genetic, bioinformatic, informatic, statistical, and molecular approaches. Current projects in the laboratory include:

1. Correlative genomic testing to support clinical trials
2. Expanded clinical applications of RNA sequencing
3. Development and application of cell-free circulating tumor nucleic acid assays

PHD PROGRAM

RESEARCH INTEREST
Drug Delivery, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Cancer Biology, Cell Signaling, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Biochemistry, Biophysics, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Biochemistry, Cancer Biology, Immunology, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Molecular Medicine, Pathology, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Chemical Biology, Immunology, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Cancer Biology, Metabolism, Pharmacology